(Q82907895)
Statements
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma (English)
F Morschhauser
P Marlton
O Lindén
J F Seymour
M Crump
B Coiffier
R Foà
E Wassner
H-U Burger
B Brennan
15 February 2010